“个人力量”与商业模式如何重塑医疗并引发新风险
How 'people power' and business transformed medicine, but created a whole new set of risks
消费驱动与商业模式正在改变药品获取方式,但常伴随监管滞后与证据不足的风险。Eli Lilly 在澳大利亚推出的 LillyDirect 平台虽提升了 Mounjaro (tirzepatide) 的可及性,却因诊疗分离引发对护理连续性的担忧。医疗可及性增长快于安全性监测体系发展,导致治疗碎片化,初级护理医生难以掌握患者通过其他渠道接受的完整用药记录。
There's been a shift in how some medicines and therapeutic products are accessed and used.
Medicinal cannabis, glucagon-like peptide-1 (GLP-1) weight-loss medicines, ketamine, psychedelics, testosterone and peptides illustrate this shift.
Increasingly, consumer demand, telehealth, social media, wellness influencers and commercial models are shaping how people learn about and access these treatments.
This is different from the traditional doctor-led model, in which medicines are generally tested, approved and included in clinical guidelines.
Now we're seeing what happens when strong consumer demand collides with commercial interests.
Improved access to certain medicines has benefits if those medicines are safe, effective and prescribed and monitored with proper oversight.
But, as we're seeing, this is not always the case.
When demand meets innovation
A recent example is the launch of LillyDirect, Eli Lilly's new Australian platform. The platform currently focuses on Mounjaro (tirzepatide), a drug used to treat type 2 diabetes and manage weight. Patients with an electronic prescription can upload it to the platform and have the medicine dispensed through an online pharmacy and delivered directly to their door.
Eli Lilly argues the model will improve affordability and convenience.
But doctors and pharmacists have raised concerns about the lack of continuity of care and what happens when prescribing, dispensing and ongoing clinical care become increasingly separated.
It is a timely example of what happens when strong consumer demand meets commercial innovation.
Ketamine is another example. It has long been used as an anesthetic. But its use for mental health conditions has expanded, including through private clinics offering ketamine treatment.
This raises questions about who is providing ketamine treatment, how patients are assessed and monitored, and whether their usual doctors know about their treatment.
These concerns don't just apply to ketamine. They relate to other drugs when uptake moves faster than the evidence of their safety and effectiveness and the development of systems needed to monitor their safety.
Patients may use a drug before we know enough about whether it works, whether there are longer-term harms, whether the drug is right for them, how it interacts with other drugs they might be taking, whether it is being monitored or when treatment should stop.
The rise of people power
Patient demand is understandable, particularly when existing treatments have not worked, are poorly tolerated or are difficult to access, or when patients feel they have not been heard.
Greater access to health information can empower patients and increase their participation in health care decisions. But access to more information does not necessarily mean access to better information.
Patients are also prepared to advocate for their own treatment. That agency is important, but it needs to sit within a system that can assess benefit, harm and appropriate use.
Stigma can also influence where people seek care. This is particularly evident with medicinal cannabis. But this also affects people with obesity, mental health conditions, menopause, sexual health concerns, hair loss and erectile dysfunction.
People who feel embarrassed or judged, or who have had their concerns previously dismissed, may be reluctant to raise them with their usual primary care doctor or seek further care. Instead, they may turn to online providers.
But patient demand should not substitute for evidence, safety monitoring or clinical oversight.
Fragmented care
Treatment may start through telehealth, an online platform or a commercial clinic.
But patients do not stop needing their usual health care. They may return to their primary care doctor with side effects, potential drug interactions, requests for laboratory testing (such as blood tests), monitoring, mental health concerns or questions about whether treatment should continue.
This can leave primary care doctors managing the consequences of treatment they did not initiate, with limited information about the treatment their patient is receiving elsewhere. When treatment is initiated elsewhere, there is often no record of it in the primary care doctor's electronic medical records.
If the treating primary care doctor cannot see what has been prescribed or dispensed, it is harder to know whether a treatment is appropriate, identify potential drug interactions and adverse effects, or recognize other safety concerns.
Medicinal cannabis illustrates this problem particularly clearly. National medicinal cannabis approval data show rapid growth in access, including for mental health conditions, chronic pain and sleep disorders.
But these data cannot tell us how many individual patients are being treated, what is actually dispensed or what happens to patients after treatment begins.
Other drugs have specific issues
Peptides are more complex. Some are increasingly promoted for wellness, anti-aging, performance and body image, despite limited evidence about their benefits and risks. For consumers, it can be difficult to tell the difference between a promising new therapy and a commercial claim that has moved ahead of the science.
Testosterone shows how treatment can also become tied to self-optimization and body image. Social media marketing promotes treatment for low testosterone ("low T") through messages about restoring youthfulness, muscularity, sexual performance and becoming a better version of yourself. This marketing also directs consumers toward testing, treatment and commercial clinics.
GLP-1 medicines are different because there is strong evidence they work for conditions such as diabetes and obesity.
But interest is rapidly expanding into other areas, including substance use disorders and Alzheimer's disease, even though these medicines are not currently approved for many of these uses.
This expansion is occurring alongside strong consumer demand, social media interest and the growth of private and online prescribing models.
Psychedelics raise similar issues around strong public interest, advocacy and commercial activity. These treatments also require clear safeguards around who should receive treatment, in which setting and how it should be monitored.
Commercial interests also need to be considered. When the same business attracts the patient, prescribes, arranges dispensing and provides follow-up, there are legitimate questions about financial incentives to prescribe and clinical independence.
Patients can demand more than access
Getting access to medicines right is not just about making them available. It also means knowing when a treatment should not be started or when it should be stopped.
This changes the conversation about consumer advocacy. Advocacy does not have to be about access alone. Patients can demand better evidence, better monitoring and safer care—from a health system that integrates their treatment choices with their everyday health care.
Equity matters too. Increased consumer access does not necessarily mean equitable access. Many of these treatments are privately funded, so access may depend heavily on the ability to pay.
What can we do?
One solution is to make better use of the health data we already collect. Primary care doctors' electronic medical records could help identify patients already using rapidly adopted treatments, track other medicines and outcomes, and identify gaps in monitoring and possible side effects.
These medical records could help connect patients to clinical trials. This way, treatments already being used in the community contribute to the evidence needed to determine whether they are effective and safe.
When demand and innovation move faster than evidence and oversight, access to medicines cannot be the only measure of progress. Access must also be appropriate, evidence-based and safe.
That means making these treatments more visible across the health system, strengthening safety monitoring and better connecting them with a patient's usual primary care doctor and the rest of their health care.
Innovation may continue to move quickly. Our systems for generating evidence and protecting patients need to move just as fast.
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Citation: How 'people power' and business transformed medicine, but created a whole new set of risks (2026, October 12) retrieved 12 October 2026 from https://medicalxpress.com/news/2026-10-people-power-business-medicine.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com